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MaOBJECTIVES The aim of this study was to assess the outcome of isolated tricuspid regurgitation (TR) and the added
value of quantitative evaluation of its severity.
BACKGROUND TR is of uncertain clinical outcome due to confounding comorbidities. Isolated TR (without signiﬁcant
comorbidities, structural valve disease, signiﬁcant pulmonary artery systolic pressure elevation by Doppler, or overt
cardiac cause) is of unknown clinical outcome.
METHODS In patients with isolated TR assessed both qualitatively and quantitatively by a proximal isovelocity
surface area method, a long-term outcome analysis was conducted. Patients with severe comorbid diseases
were excluded.
RESULTS The study involved 353 patients with isolated TR (age 70 years; 33% male; ejection fraction, 63%; all with
right ventricular systolic pressure <50 mm Hg). Severe isolated TR was diagnosed in 76 patients (21.5%) qualitatively and
68 patients (19.3%) by quantitative criteria (effective regurgitant oriﬁce [ERO] $40 mm2). The 10-year survival and
cardiac event rates were 63  5% and 29  5%. Severe isolated TR independently predicted higher mortality (adjusted
hazard ratio: 1.78 [95% conﬁdence interval (CI): 1.10 to 2.82], p ¼ 0.02 for qualitative deﬁnition and 2.67 [95% CI: 1.66
to 4.23] for an ERO $40 mm2, p < 0.0001). The addition of grading by quantitative criteria in nested models eliminated
the signiﬁcance of the qualitative grading and improved the model prediction (p < 0.001 for survival and p ¼ 0.02
for cardiac events). The 10-year survival rate was lower with an ERO $40 mm2 versus <40 mm2 (38  7% vs. 70  6%;
p < 0.0001), independent of all characteristics, right ventricular size or function, comorbidity, or pulmonary pressure
(p < 0.0001 for all), and lower than expected in the general population (p < 0.001). Freedom from cardiac events was
lower with an ERO $40 mm2 versus <40 mm2 independently of all characteristics, right ventricular size or function,
comorbidity, or pulmonary pressure (p < 0.0001 for all). Cardiac surgery for severe isolated TR was rarely performed
(16  5% 5 years after diagnosis).
CONCLUSIONS Isolated TR can be severe and is associated with excess mortality and morbidity, warranting heightened
attention to diagnosis and quantitation. Quantitative assessment of TR, particularly ERO measurement, is a powerful
independent predictor of outcome, superior to standard qualitative assessment. (J Am Coll Cardiol Img 2014;7:1185–94)
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ABBR EV I A T I ON S
AND ACRONYMS
ERO = effective regurgitant
oriﬁce
RV = right ventricular
SPAP = systolic pulmonary
artery pressure
TR = tricuspid regurgitation
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1186T ricuspid regurgitation (TR) is fre-quent (1) but poorly deﬁned. Man-agement guidelines remain vague
(2) due to a paucity of outcome studies and
their contradictory results (3–6). Studies of
TR are inﬂuenced by outcome interference
of numerous comorbidities, pulmonary hy-
pertension, left-sided heart disease, and
background conditions (4,7,8) that obscurethe speciﬁc signiﬁcance of TR (9). Thus, it is generally
uncertain whether TR independently affects outcome
or is a surrogate for associated conditions. Other
sources of uncertainty are the imprecision of stan-
dard assessment of TR (10) and the ambiguity of
guidelines in deﬁning severe TR (11). Hence, clinical
guidelines propose very limited indications for
tricuspid valve surgery unless there is another surgi-
cal indication such as severe mitral valve diseases (2).SEE PAGE 1195In trying to resolve this conundrum, we assessed
patients with isolated functional TR, excluding major
comorbidities affecting TR outcome (9,12–14) and with
TR quantitative assessment (11,15,16). We aimed to
evaluate clinical outcome of isolated TR, deﬁne
whether severe isolated TR is associated with excess
mortality and cardiac events, and analyze the role of
TR quantitative assessment in predicting TR outcome.
METHODS
DEFINITION OF ISOLATED TR. Isolated TR diagnosis
required the following: 1) TR holosystolic and func-
tional; 2) no likely pulmonary hypertension
(<50 mm Hg) (17); 3) no overt TR cause (no intrinsic
tricuspid disease, left ventricular ejection fraction
$50%, no pacemaker/deﬁbrillator wire across the
tricuspid, no other valve disease more than mild, no
disease that may cause TR, no congenital or peri-
cardial heart disease); and 4) no previous valve
surgery.
STUDY DESIGN. We initiated a prospective program
of TR quantitation enrolling patients with mild or
greater holosystolic TR by visual assessment. The
ﬁnal population was selected retrospectively as pa-
tients with isolated TR and TR quantitation per-
formed from 1995 to 2005. Patients with severe
comorbid conditions, including cancer, severe lung
disease, cirrhosis, recent myocardial infarction
(<3 months), or end-stage renal disease at presenta-
tion were excluded. Isolated quantiﬁed mild to severe
TR represented 12.2% of our quantiﬁed population.
We also identiﬁed 1,972 patients with trivial isolated
TR (jet area #1.0 cm2; an effective regurgitant oriﬁce[ERO] of 0) evaluated by the principal investigator,
during the same period, with same inclusion criteria
and same methods. To examine the hypothesis that
isolated TR of increasing quantiﬁed degree is associ-
ated with worse outcome consequences, a frequency-
matching approach was used in which patients with
trivial isolated TR were randomly selected from the
desired bin of all patients with trivial isolated TR,
achieving groups of patients with trivial and mild to
severe quantiﬁed TR comparable in terms of other
independent determinants of outcome but with no
set couples of matched patients and unequal size.
The predeﬁned baseline computerized matching pa-
rameters were age (within 10 years), ejection fraction
(within 5%), exact year of diagnosis, atrial ﬁbrillation,
and sex.
Outcome was analyzed from an echocardiographic
diagnosis until death or last follow-up up to 2010.
The study was powered (80%, p ¼ 0.05) to detect
$30% mortality difference between severe and lesser
degrees of isolated TR. The study was institutional
review board approved.
BASELINE CLINICAL ASSESSMENT AND MANAGEMENT.
Patient symptoms, physical examination, and co-
morbid conditions (Charlson age-adjusted comorbid-
ity index [18]) were evaluated by Mayo personal
physicians. Congestive heart failure was diagnosed by
Framingham criteria (19). Clinical management was
determined by personal physicians.
FOLLOW-UP AND OUTCOMES. Clinical follow-up
was obtained by review of medical records, surveys,
and telephone interviews. The cause of death was
determined by medical records and death certiﬁcates.
Events used as endpoints were mortality and cardio-
vascular events under medical management. Cardio-
vascular events comprised cardiac death including
sudden death (20) and congestive heart failure but
not death due to other causes.
DOPPLER ECHOCARDIOGRAPHY. All measurements
were averages of inspiratory and expiratory (21)
over $5 cardiac cycles (22,23). Right ventricular (RV)
size and systolic function were qualitatively graded
(on a scale of 1 to 4). RV function assessment was on
the basis of multiple views of the right ventricle
(short-axis parasternal at basal, mid, and apical
levels; lower parasternal RV inﬂow view; apical 4-
chamber view; and, if possible, RV long-axis view
and subcostal short- and 4-chamber views). Using
these multiple views, integrative qualitative grading
was formulated by the physician responsible for the
echocardiogram. Qualitative TR assessment used jet
size, vena contracta (24), and hepatic venous reversal
using recent American Society of Echocardiography
TABLE 1 Baseline Characteristics of Patients With Functional TR Overall
and Stratiﬁed by Severity of Regurgitation
All Isolated
Functional TR
(N ¼ 353)
Trivial Isolated
Functional TR
(n ¼ 211)
Mild to
Severe Isolated
Functional TR
(n ¼ 142) p Value
Age, yrs 70  14 70  14 71  14 0.26
Atrial ﬁbrillation 157 (44) 95 (45) 62 (44) 0.80
Male 115 (33) 71 (34) 44 (31) 0.60
Systolic blood pressure, mm Hg 129  20 130  19 128  20 0.36
Hemoglobin, g/l 13.3  1.6 13.4  1.7 13.1  1.6 0.07
Creatinine, mg/dl 1.13  0.5 1.12  0.3 1.14  0.7 0.68
Bilirubin, mg/dl 0.71  0.4 0.75  0.5 0.68  0.3 0.20
Ejection fraction, % 63  6 64  6 63  6 0.12
Age/comorbidity index 4.7  3.0 4.7  2.8 4.7  3.2 0.80
Values are mean  SD or n (%).
TR ¼ tricuspid regurgitation.
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1187guidelines criteria (11,15,24). TR quantitation used a
proximal ﬂow convergence method as validated pre-
viously (11,15,16,24). To measure the ﬂow conver-
gence, the color-ﬂow velocity scale was maximized,
and the baseline was shifted downward until the ﬂow
convergence region was clearly visualized. All
possible views were used to obtain the best alignment
of ﬂow center line with the beam of ultrasound. We
then recorded cines of ﬂow convergence imaging in
zoomed views and measured on these loops multiple
ﬂow convergence radii, in inspiration and expiration,
timed to peak TR velocity (generally on the T-wave of
the electrocardiogram). Corrections for the angle of
leaﬂets and for the ratio of aliasing velocity to peak
TR velocity (peak velocity)/(peak velocity  aliasing
velocity) were applied (21), allowing calculation of
regurgitant ﬂow. The ERO area was calculated as the
ratio of regurgitant ﬂow to the peak velocity of the TR
jet and the regurgitant volume as the product of the
ERO  the regurgitant time-velocity integral.
STATISTICAL ANALYSIS. Descriptive results were
expressed as mean  SD (continuous variables) and
percents (categorical variables). Group comparisons
used analysis of variance, Fisher exact, or the chi-
square test, as appropriate. Multiple comparisons
for continuous and categorical parameters used
Tukey-Kramer honestly signiﬁcant difference test
and Bonferroni correction, respectively. Analysis
of association of severe TR with outcome was
based primarily on quantitative TR deﬁnition (ERO
$40 mm2), but standard qualitative classiﬁcation was
also used and incremental value tested by nested
models with F tests. Endpoints were death of any
cause and cardiac events under medical management
(from diagnosis to surgery or death), and data were
censored at the time of cardiac surgery if it was per-
formed or at the time of noncardiac death. Event rates
were estimated by the Kaplan-Meier method
and compared by the log-rank test. Comparison
of observed to expected mortality used U.S.
Census-Bureau life tables and the log-rank test. Cox
proportional hazards models calculated hazard ratios
associated with severe TR, unadjusted and adjusted
for age, sex, ejection fraction, pulmonary pressure,
RV size, RV function, and atrial ﬁbrillation, which
were selected a priori and hierarchical on the basis of
their biological impact on survival. Values of p < 0.05
were considered signiﬁcant.
RESULTS
BASELINE CHARACTERISTICS. Table 1 shows base-
line characteristics of the 353 patients, overall and
stratiﬁed as patients with quantiﬁed isolated TR (mildto severe quantiﬁed TR) versus patients with trivial
TR. Age, sex, ejection fraction, systolic blood pres-
sure, hemoglobin, bilirubin, age/comorbidity index,
and atrial ﬁbrillation were equally distributed. Dys-
pnea, chest pain, and ankle swelling were more
frequent in patients with more than trivial isolated TR
(all p values <0.001). However, there was no differ-
ence in symptoms between trivial and mild to mod-
erate (ERO, 1 to 39 mm2) TR.
Clinical and echocardiographic assessments clas-
siﬁed by quantitative grades of TR are presented in
Table 2. The prevalence of murmur increased with
severe regurgitation but rarely with inspiratory
variation. Heart failure was more prevalent in
severe TR despite greater use of diuretic agents
(41% vs. 16% and 13% in mild to moderate and
trivial TR, p < 0.0001). Similar to mitral regurgita-
tion (25) in isolated TR, enlarged RV end-diastolic
and end-systolic areas with worsening TR reﬂect
altered end-systolic characteristics but allow
increased regurgitant volume, whereas cardiac index
decreases little and RV area contraction displays
nonsigniﬁcant changes. Hemodynamic assessment
showed signiﬁcant but slight systolic pulmonary
pressure differences with averages well within un-
likely pulmonary hypertension and in all patients
below thresholds deﬁning likely pulmonary hyper-
tension (17).
SURVIVAL AFTER DIAGNOSIS. There were 82 deaths
under medical management during follow-up (5.8 
3.2 years). Quantiﬁed TR degree was strongly associ-
ated with decreased survival (Table 3). However, the
ERO was a more powerful predictor of survival than
regurgitant volume (p < 0.01) so that all subsequent
analyses focused on the ERO.
TABLE 2 Objective Tricuspid-Related Clinical and Echocardiographic Characteristics
Isolated Tricuspid Regurgitation Severity
p Value
Trivial
(n ¼ 211)
Mild-Moderate
(n ¼ 74)
Severe
(n ¼ 68)
Clinical characteristics
Systolic murmur, % 27 35 68*† <0.0001
Inspiratory increase of
murmur, %
0.5 4.0 15*† <0.0001
Increased jugular venous
pressure, %
2 14* 38*† <0.0001
Hepatojugular reﬂux, % 0.5 4 19*† <0.0001
Edema, % 13 12 49*† <0.0001
Heart rate, beats/min 75.4  17.4 71.3  17.2 72.0  17.8 0.14
Doppler echocardiography
characteristics
Effective regurgitant
oriﬁce, mm2
0 27  8* 68  37*† <0.0001‡
Regurgitant volume,
ml/beat
0 23.7  7.9* 51.4  18.0*† <0.0001‡
Jet area, cm2 <1 6.6  3.5* 10.4  4.9*† <0.0001‡
Vena contracta, mm <2 4.8  1.6* 6.7  2.6*† <0.0001‡
Tricuspid regurgitant
peak velocity, m/s
2.5  0.3 2.7  0.3* 2.6  0.3* <0.0001
Estimated right atrial
pressure, mm Hg
6.0  2.1 8.9  4.0* 11.9  5.6*† <0.0001
Right ventricular systolic
pressure, mm Hg
30.7  6.0 39.3  6.9* 40.0  6.8* <0.0001
Cardiac index, l/min/m2 2.9  0.7 2.8  0.7 2.6  0.5* 0.002
E/A ratio 1.04  0.5 1.06  0.5 1.1  0.5 0.9
E/e0 11.8  0.3 11.7  4.3 11.6  4.1 0.9
Diastolic grade, % 0, 11; I, 37;
II, 52
0, 16; I, 38;
II, 45
0, 10; I, 27;
II, 62
0.3
RV enlargement moderate
or severe, %
2 19* 40*† <0.0001
RV end-diastolic area
indexed, cm2/m2
11.9  2.5 13.9  3.3 17.0  0.5*† <0.0001
RV end-systolic area
indexed, cm2/m2
6.7  2.0 8.6  2.3 10.8  4.1*† <0.0001
RV function reduction
moderate or severe, %
0 4 4.5§ 0.004
RV fractional area
change, %
44.5  8.0 38.0  11.0 37.2  11.0 0.2
RIMP 0.32  0.08 0.42  0.18 0.44  0.2 0.3
Values are mean  SD. Mild-moderate and severe tricuspid regurgitation are deﬁned on the basis of effective
regurgitant oriﬁce 1 to 39 mm2 and $40 mm2 respectively. *p < 0.001 versus trivial TR. †p < 0.001 versus
mild-moderate isolated TR. ‡p < 0.05. §p < 0.05.
E/A ¼ ratio of mitral inﬂow peak early diastolic ﬂow-velocity to atrial contraction peak-velocity; E/e0 ¼ ratio of
mitral inﬂow peak early diastolic ﬂow-velocity to septal mitral-annulus tissue Doppler early diastolic-velocity;
RIMP ¼ right ventricular index of myocardial performance RV ¼ right ventricular.
TABLE 3 Impact of Clinical and Echocardiographic
Characteristics on Mortality in Patients With Idiopathic
Isolated Tricuspid Regurgitation
HR (95% CI) p Value
Effective regurgitant oriﬁce, cm2 3.50 (2.20–5.20) <0.0001
Regurgitant volume, ml/beat 1.02 (1.01–1.03) <0.0001
Tricuspid regurgitant peak velocity, m/s 1.03 (0.99–1.06) 0.08
Estimated right atrial pressure, mm Hg 1.07 (1.02–1.12) 0.003
Right ventricular systolic pressure, mmHg 1.04 (1.02–1.07) 0.001
Cardiac index, l/min/m2 0.83 (0.60–1.13) 0.2
E/A ratio 1.00 (0.40–2.06) 0.9
E/e0 1.06 (1.00–1.11) 0.05
Diastolic grade — 0.02
RV size (visual estimation) — 0.01
RV end-diastolic area indexed, cm2/m2 1.10 (1.03–1.17) 0.002
RV end-systolic area indexed, cm2/m2 1.14 (1.04–1.23) 0.007
RV function (visual estimation) — 0.03
RV fractional area change, % 3.90 (0.25–6.20) 0.3
RIMP 1.03 (0.20–5.20) 0.9
CI ¼ conﬁdence interval; HR ¼ hazard ratio; RIMP ¼ right ventricular index of
myocardial performance; RV ¼ right ventricular; other abbreviations as in Table 2.
TABLE 4 Impact of Severe Regurgitation (Effective Regurgitant
Oriﬁce $40 mm2) on Mortality and Cardiovascular Events Risk
After the Diagnosis of Idiopathic Isolated Tricuspid Regurgitation
HR 95% CI p Value
Mortality after diagnosis
Univariable analysis 3.34 2.12–5.20 <0.001
Adjusted* 2.67 1.66–4.23 <0.001
Comprehensive adjustment† 2.95 1.67–5.19 <0.001
Cardiac events
Univariable analysis 6.62 3.87–11.46 <0.001
Adjusted‡ 3.98 2.15–7.45 <0.001
Comprehensive adjustment† 4.77 2.40–9.60 <0.001
*Adjustment was for age, systolic blood pressure, and the presence of atrial ﬁbril-
lation. †Adjustment was for age, sex, systolic blood pressure, history of coronary
disease, symptoms at diagnosis, Charlson comorbidity index, left ventricular ejec-
tion fraction, right ventricular size, right ventricular function, and right ventricular
systolic pressure. ‡Adjustment was for age, systolic blood pressure, symptoms,
right ventricular systolic pressure, and the presence of atrial ﬁbrillation.
Abbreviations as in Table 3.
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1188Clinical characteristics predictive of higher mor-
tality were older age (adjusted hazard ratio [HR]: 1.09
[95% conﬁdence interval (CI): 1.06 to 1.12] per year;
p < 0.001), lower systolic-blood-pressure (adjusted
HR: 0.98 [95% CI: 0.99 to 0.97] per mm Hg; p ¼ 0.02),
symptoms (adjusted HR: 2.0 [95% CI: 1.3 to 3.0]; p <
0.01), and atrial ﬁbrillation at diagnosis (adjusted
HR: 1.77 [95% CI: 1.14 to 2.79], p ¼ 0.01). Echo-
cardiographic characteristics predictive of higher
mortality are shown in Table 3. Addition of the
ERO to models showed severe TR ($40 mm2)independently associatedwith lower survival (Table 4)
with improved model predictive power (p< 0.001).
Mild to moderate isolated TR showed no difference
in survival after diagnosis versus trivial regurgitation,
univariably (86  3% vs. 90  4% at 5 years, p ¼ 0.23)
or in multivariable models (p ¼ 0.34). Subdivision of
the mild to moderate range into mild (1 to 19 mm2)
and moderate (20 to 39 mm2) did not yield survival
differences (p ¼ 0.42). Kaplan-Meier survival curves
(Figure 1) show considerable survival difference
between severe and lesser degrees of isolated TR
(ERO $40 mm2 vs. <40 mm2).
Overall, observed versus expected survival was not
different (63% vs. 62% expected at 10 years, p ¼ 0.80).
Years
Su
rv
iv
al
 (%
)
100
80
60
40
20
0
0 2 4 6 8 10
Number at Risk
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ERO <40  285 253 210 163 46 23
 68 55 42 31 24 8
p < 0.001
66 ± 6%
38 ± 7%
87 ± 2%
70 ± 6%
ERO < 40 mm2mm2
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FIGURE 1 Survival in Patients With Isolated TR, Stratiﬁed According to ERO
Overall survival in patients with isolated tricuspid regurgitation (TR) stratiﬁed according to
the effective regurgitant oriﬁce (ERO). Severe with ERO $40 mm2 (dashed line) versus
trivial to moderate with ERO <40 mm2 (solid line). The values indicated for each line are
survival rates (SE) at 5 and 10 years.
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FIGURE 2 Cardiac Events (Cardiac Death or Congestive Heart Failure) in Patients
With Isolated TR, Stratiﬁed According to the ERO
The values indicated for each line are cardiac event rates ( SE) at 5 and 10 years. Note
that there is no difference in cardiac event rates between patients with trivial, mild, and
moderate isolated TR (p ¼ 0.58), but that severe TR is associated with markedly increased
cardiac event rates. Abbreviations as in Figure 1.
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1189The only group with observed less than expected
survival was that with an ERO $40 mm2 (38% vs. 58%
expected at 10 years, p < 0.001).
CARDIAC EVENTS AFTER DIAGNOSIS. During
follow-up under conservative management, 55 pa-
tients experienced cardiac events, 20 heart failure,
and 45 cardiac death or both. The ERO of TR was
strongly associated with higher event rates (Table 4).
Background clinical and echocardiographic char-
acteristics predictive of higher event rates were older
age (adjusted HR: 1.08 [95% CI: 1.05 to 1.12] per year;
p < 0.001), lower systolic blood pressure (adjusted
HR: 0.98 [95% CI: 0.97 to 0.99] per mm Hg; p ¼ 0.02),
symptoms (adjusted HR: 3.3 [95% CI: 1.9 to 5.6]; p <
0.001), atrial ﬁbrillation at diagnosis (adjusted HR:
2.8 [95% CI: 1.6 to 4.7]; p < 0.01) and RV systolic-
pressure (adjusted HR: 1.09 [95% CI: 1.05 to 1.13] per
mm Hg; p < 0.01). Addition of the ERO to models
showed severe TR ($40 mm2) independently associ-
ated with higher event rates (Table 4) and increased
model predictive power (p < 0.001). Mild to moderate
versus trivial isolated TR showed no differences in
cardiac events univariably (6  3% vs. 6  2% at
5 years, p ¼ 0.33) or multivariably (p ¼ 0.16). Subdi-
vision of mild to moderate range into mild and
moderate showed no difference in events (p ¼ 0.39).
Kaplan-Meier curves (Figure 2) show considerably
higher cardiac event rates after diagnosis in severe
versus lesser isolated TR. Severe TR (ERO >0.4 cm2)
was associated with an increased rate of sudden
death (hazard ratio: 3.5 [95% CI: 1.6 to 7.6];
p ¼ 0.003). The 5-year rate of sudden death was 3.0 
1.0% versus 14.5  4.0%; p ¼ 0.008 for patients with
an ERO <0.4 cm2 and an ERO >0.4 cm2, respectively.
SUBGROUP ANALYSIS. Outcomes in sinus rhythm
and atrial ﬁbrillation are shown Figure 3, demon-
strating similarly lower survival and higher cardiac
event rates with severe isolated TR irrespective of
rhythm at baseline. Multivariable analysis stratiﬁed
by baseline rhythm shows that severe isolated TR
independently determines lower survival in sinus
rhythm (adjusted HR: 2.2 [95% CI: 1.02 to 5.7]; p ¼
0.01) and atrial ﬁbrillation (adjusted HR: 3.7 [95%
CI: 1.4 to 11.7]; p ¼ 0.004) with higher cardiac event
rates in sinus rhythm (adjusted HR: 3.5 [95% CI: 1.4
to 8.8]; p ¼ 0.002) and atrial ﬁbrillation (adjusted
HR: 3.3 [95% CI: 1.3 to 10.1]; p ¼ 0.001).
Patients were also stratiﬁed by symptom status
as asymptomatic (65%) or symptomatic (35%). Sur-
vival and cardiac event rates were worse in patients
with symptoms at baseline. The 5-year survival rate
was 84.7  2.5% versus 77.6  3.9% in asymptom-
atic versus symptomatic isolated TR (p ¼ 0.001),
and freedom from cardiac events was 93.3  1.8%
ERO < 40 mm2mm2
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FIGURE 3 Survival and Cardiac Events in Patients With Isolated TR, Stratiﬁed According to ERO and Baseline Rhythm
Outcome of patients with isolated TR, stratiﬁed by atrial rhythm at diagnosis (sinus rhythm, [left] and atrial ﬁbrillation [right]) comparing those
with severe versus trivial to moderate TR deﬁned by the ERO. The graphs in the top row indicate overall survival, and those in the bottom row
indicate cardiac events. Note that there is trend toward more deaths and cardiac events in atrial ﬁbrillation. However, in both atrial ﬁbrillation
and sinus rhythm, severe TR is associated with markedly decreased survival and markedly increased cardiac events. Abbreviations as in Figure 1.
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1190versus 80.5  3.9% in asymptomatic versus symp-
tomatic patients (p < 0.0001). Outcomes in symp-
tomatic and asymptomatic patients (Figure 4) show
lower survival and higher cardiac event rates with
severe isolated TR ($40 mm2 vs. <40 mm2) in both
symptom strata, conﬁrmed on multivariable anal-
ysis for survival (both p < 0.01) and cardiac events
(both p < 0.001).
We followed the most recent guidelines (17) spec-
ifying that pulmonary hypertension is “likely” with a
systolic pulmonary artery pressure (SPAP) >50
mm Hg so that such patients were carefully excluded;
219 patients fulﬁlled criteria for “unlikely pulmonary
hypertension” (SPAP #36 mm Hg), and 134 were
“possible pulmonary hypertension” of 37 to 49
mm Hg. Comparing the “unlikely” and “possible”
groups, the 5-year survival rate was similar without
severe TR (ERO <0.4 cm2), 86  3% versus 88  3%
(p ¼ 0.6) and with severe TR (ERO >0.4 cm2), 54 
13% versus 61  7% (p ¼ 0.5). Multivariable analysisshowed that SPAP among our patients did not inde-
pendently determine mortality (p ¼ 0.08) or cardiac
events (p ¼ 0.09). Stratiﬁed by SPAP, severe isolated
TR (ERO >0.4 cm2) is associated with a lower survival
rate with SPAP <36 mm Hg (5-year 54% vs. 86%, p <
0.001) or >36 mm Hg (5-year 61% vs. 88%, p < 0.001).
Similarly, severe isolated TR is associated with higher
cardiac event rates with SPAP <36 mm Hg (5-year
33% vs. 5%, p < 0.001) or >36 mm Hg (5-year 31%
vs. 5%, p < 0.001). Cox proportional hazard analysis
with interaction terms for ERO (<0.4 cm2 or $0.4
cm2) and SPAP (<36 mm Hg or $36 mm Hg) showed
that SPAP level does not affect severe isolated TR
impact on survival (p ¼ 0.4) or cardiac events (p ¼
0.33). On Cox proportional analysis limited to pa-
tients with SPAP #36 mm Hg, severe TR is highly
signiﬁcantly associated with survival (p < 0.001) and
cardiac events (p < 0.001) on unadjusted analysis and
adjusted analysis (p ¼ 0.005 for survival and p ¼ 0.02
for cardiac events).
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FIGURE 4 Survival and Cardiac Events in Patients With Isolated TR, Stratiﬁed According to ERO and Baseline Symptoms
Outcomes of patients with isolated TR, stratiﬁed by symptoms at diagnosis (asymptomatic [left] and symptomatic [right]) comparing those
with severe versus trivial to moderate TR deﬁned by the ERO. The graphs in the top row indicate overall survival after diagnosis, and the
graphs in the bottom row indicate cardiac events after diagnosis. The p values were #0.001 for all comparisons. Abbreviations as in Figure 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 2 , 2 0 1 4 Topilsky et al.
D E C E M B E R 2 0 1 4 : 1 1 8 5 – 9 4 Outcome of Isolated TR
1191QUANTITATIVE VERSUS QUALITATIVE GRADING OF
SEVERE ISOLATED TR. There were 76 patients
graded severe TR qualitatively, and agreement with
quantitative grading was signiﬁcant but suboptimal
(kappa ¼ 0.65, p < 0.01). Severe TR by qualitative
criteria was associated with a lower survival rate
(45  8% vs. 69  6% at 10 years, p < 0.001), con-
ﬁrmed on multivariable analysis (adjusted HR: 1.78
[95% CI: 1.10 to 2.82], p ¼ 0.02) and with higher event
rates (57  8% vs. 18  5% at 10 years, p < 0.001)
conﬁrmed on multivariable analysis (adjusted HR:
3.84 [95% CI: 2.13 to 7.00], p < 0.001). However, for
both endpoints, addition of severe grading by quan-
titative criteria in nested models eliminated qualita-
tive grading signiﬁcance and improved model
prediction (p < 0.001 for survival and p ¼ 0.02 for
cardiac events).
CLINICAL MANAGEMENT AND SURGERY. Clinical
management after diagnosis was medical in 341 pa-
tients (97%) and by tricuspid surgery (mean 0.9  1.7years later) in 12 patients. Surgical indication was
on the basis of severe right heart failure symptoms
in 7 patients, marked RV dilation in 2 patients, or
other indication for cardiac surgery in 3 patients.
TR was severe at surgery in all patients who were
operated on, and valve repair was performed in
8 (66%) with replacement in the other 4 patients.
DISCUSSION
Our study, the ﬁrst to link quantiﬁed TR and clinical
outcome, shows that the outcome of isolated
severe functional TR, independently of other cardio-
vascular or comorbid conditions, is characterized by
excess mortality and excess cardiac events. This in-
dependent negative outcome is obvious with any
group stratiﬁcation: symptoms, rhythm, or SPAP.
Conversely, no adverse consequence could be detec-
ted regarding moderate isolated TR, further empha-
sizing the importance of precise TR assessment. TR
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1192quantitative assessment, particularly ERO measure-
ment, is the most powerful predictor of outcome,
superior to standard qualitative assessment. How-
ever, this comparative issue should not overshadow
the most important goal of detecting severe TR by any
means possible and should raise awareness of its dire
consequences.
TR HETEROGENEITY AND OUTCOME UNCERTAINTY.
Assessing the clinical impact of TR is difﬁcult because
it is heterogeneous (26), variably associated with
intrinsic valve lesions (27), pulmonary hypertension,
ventricular dysfunction, and comorbid or causal dis-
eases (9) that have confused previous attempts to
deﬁne the TR-speciﬁc impact on outcome (3,5,6). The
largest outcome study to date suggested that TR of
any type may affect outcome (6), but a TR dire
outcome could just reﬂect associated conditions. This
uncertainty is further complicated by the imprecision
of qualitative grading of TR (10,11,28).
To ﬁll these gaps in knowledge, we designed this
study with careful patient selection to minimize het-
erogeneity of TR etiology and mechanism and to
minimize the impact of comorbid conditions (9,12–14).
This process yields robust evidence that severe
isolated TR implies excess subsequent mortality and
cardiac events. Importantly, using multiple methods,
the conceptual heterogeneity in pulmonary hyper-
tension (unlikely vs. possible) did not affect our
results, speciﬁcally, severe isolated TR affects sub-
sequent outcome irrespective of the included SPAP
range, which does not bias the TR role. Our data raise
the question of whether severe TR of any cause or
mechanism may have similar dire consequences
independently of the comorbid or causal disease
involved (6), but strict relevance is to isolated TR,
which deserves particular attention.
ASSESSMENT OF TR. TR is often clinically unsus-
pected (4,26) and cardiac auscultation is rarely
typical. Thus, in routine practice, diagnosis mostly
depends on Doppler echocardiography (29). For this
purpose, we prefer quantitative grading of TR. The
threshold of an ERO of 40 mm2 was suggested by
physiological studies (16), but the present data are
the ﬁrst to link this threshold to outcome, survival,
and cardiac events, and its prognostic power super-
sedes that of classic semiquantitative grading (11).
However, although weaker, qualitative deﬁnition of
severe TR also predicted outcome and is important
in alerting to the condition and to the need for quan-
titative assessment (11). Importantly, TR severity
may vary due to RV plasticity and varying load. RV
widening and annular enlargement decrease systolic
annular coverage by leaﬂets, increasing TR. Hence,
persistence of severe functional TR despite treatmentis important in therapeutic decisions (30), as less se-
vere TR is associated with preserved outcome, em-
phasizing the signiﬁcance of precise TR assessment.
ETIOLOGY OF ISOLATED TR. The etiology of isolated
TR is not well characterized because exceptional re-
ferrals to surgery prevent direct pathological obser-
vation (27). Isolated TR was mentioned in several
reports (12–14), which described an appearance that is
quite different from that of functional TR caused by
pulmonary hypertension (9,31) and that of associated
right ventricular remodeling, which are fundamen-
tally different (31). With pulmonary hypertension,
the right ventricle becomes globular, leading to
tethering of tricuspid leaﬂets (32), similar to func-
tional mitral regurgitation (33). Conversely, isolated
TR is characterized by dilation of the RV base and
tricuspid annulus, leading to less tethering but
exhaustion of the reserve of valvular coverage of the
annulus (14,31,34). The exact pathological mechanism
of annular enlargement is undeﬁned and may be a
degenerative alteration of tricuspid annular ﬁbrous
structure (35). Importantly, we show that, irre-
spective of mechanistic issues and despite a benign
façade (17), isolated TR may be severe and may seri-
ously affect outcome.
CLINICAL IMPLICATIONS. Although seminal reports
suggested that untreated TR is an important con-
tributor to poor outcome (3,5,6,16), the present study
provides evidence for the ﬁrst time that severe iso-
lated TR, irrespective of SPAP level, is associated
with excess mortality and cardiac events when it is
severe. Furthermore, we show that measurement of
ERO using quantitative Doppler echocardiography
methods provides the most powerful tools for strati-
ﬁcation and management. The ERO threshold of
40 mm2 is linked to clinical outcome, survival, and
cardiac events. No adverse consequence could be
detected regarding moderate TR (<40 mm2) in the
speciﬁc context of isolated TR, suggesting that, in this
context, moderate TR can be treated conservatively
and emphasizing the importance of TR quantitative
assessment. In view of the observation, unencum-
bered by signiﬁcant SPAP elevation by Doppler
echocardiography or other comorbidity, of this
very strong link to TR outcome, future studies
should examine whether these strong conclusions
can be applied to other well-deﬁned subsets of
patients with TR.
STUDY LIMITATIONS. Quantitation of TR performed
as clinically required may cause selection bias but
represents standard clinical practice. Doppler echo-
cardiography to assess systolic pulmonary pressure in
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1193the presence of severe TR may be questioned but is
reliable to exclude likely pulmonary hypertension
(36) and is part of present guidelines (17). Atrial
ﬁbrillation is frequent in isolated TR (14), but was
carefully matched among TR groups and does not
affect the TR impact on outcome. The comprehensive
multivariate mortality analysis is potentially over-
ﬁtted, which may result in lower predictive perfor-
mance. At the time of patient enrollment, routine RV
assessment did not include the tricuspid annular
plane systolic excursion, Doppler-derived tricuspid
lateral annular systolic velocity (S0), or 3-dimensional
RV ejection fraction, the prognostic value of which
will warrant prospective studies of isolated TR in the
future. Afﬁrming isolated functional TR requires
comprehensive imaging of the tricuspid valve, which
may be facilitated by up-to-date 3-dimensional im-
aging software. Magnetic resonance imaging is
particularly suited for analyzing RV function but
could not be implemented systematically. Future
studies using combined imaging with magnetic reso-
nance imaging or new 3-dimensional imaging soft-
ware to assess RV in isolated functional TR quantiﬁed
by Doppler echocardiography will be essential to
provide combined RV and TR assessment (22).
Guidelines do not provide class I indications for sur-
gery of isolated, even severe, functional TR (2), andfew patients were referred for surgery. We believe
that our data support the rationale to consider sur-
gery for severe isolated functional TR and more
generally severe TR, even if not associated with
left-sided valve diseases. Nevertheless, a clinical trial
should be conducted to afﬁrm the impact of tricuspid
surgery on outcome.
CONCLUSIONS
Isolated functional TR may be severe or even
massive. Such patients, despite a benign appearance,
have a poor outcome when TR is severe with excess
mortality and high morbidity. Awareness of the con-
dition is low and echocardiographic detection of
severe, isolated TR, although best done with quanti-
tative methods, should take advantage of all infor-
mation available. Hence, this condition requires
active detection by Doppler echocardiography and
quantiﬁcation of the severity of TR and should be
closely monitored.
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